StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026Score 5/3085% above fair value
$430.36−1.34 (-0.31%)

Close on Oct 30, 2026Market cap $9.94BP/E –Yield –

Earnings

Madrigal Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 3, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$364.30M
+71.2% on a year earlier
EPS, Q2 FY2026
$1.99
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Madrigal Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 3, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Jul 30, 2026before the open$364.30M+71.2%$1.99Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$311.30M+126.7%-$3.25Release
Q4 FY2025ended Dec 31, 2025Feb 19, 2026before the open$321.10M+210.8%–Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open$287.30M+361.9%–Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$212.80M+1357.5%–Release
Q1 FY2025ended Mar 31, 2025May 1, 2025before the open$137.30M––Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025before the open$103.30M–-$2.71Release
Q3 FY2024ended Sep 30, 2024Oct 31, 2024before the open$62.20M–-$4.92Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$14.60M–-$7.10Release
Q1 FY2024ended Mar 31, 2024May 7, 2024before the open––-$7.38Release
Q4 FY2023ended Dec 31, 2023Feb 28, 2024before the open––-$5.68Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Madrigal Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Madrigal Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Madrigal Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
    Update
  2. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
    Results
  3. Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates
    Results
  4. Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
    Results
  5. Madrigal Pharmaceuticals Reports Third -Quarter 2025 Financial Results and
    Results
  6. Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and
    Results
  7. Madrigal Pharmaceuticals Enters into Exclusive
    Update
  8. Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
    Update
  9. Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
    Results
  10. Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
    Update
  11. Quarterly results release
    Results
  12. Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024
    Results
  13. Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
    Results
  14. Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
    Results
  15. Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
    Results